A Phase Ib, Open-Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients with Non-Small Cell Lung Cancer with Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa)
What is the purpose of this trial?
- 18 Years and older
- Boehringer Ingelheim Pharmaceuticals
- April 2011
- Last Updated:
- Study HIC#:
Clinicaltrials.gov ID: Yale3785320